Stella Diagnostics, Inc. (SLDX)
| Market Cap | 3.02M -50.0% |
| Revenue (ttm) | n/a |
| Net Income | -257.97K |
| EPS | -7.53 |
| Shares Out | 301.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.0100 |
| Previous Close | 0.0081 |
| Day's Range | 0.0100 - 0.0100 |
| 52-Week Range | 0.0051 - 0.0370 |
| Beta | -0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Stella Diagnostics
Stella Diagnostics, Inc., a research diagnostics company, engages in developing molecular diagnostics tools and new drug targets for esophageal diseases. It uses targeted mass spectrometry to determine the level of disease progression in tissue of the lower esophagus. The company’s technology informs gastroenterologists, surgical oncologists, and pathologists, which patients are high risk for disease progression into precancer or cancer. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in A... [Read more]
Financial Performance
Financial StatementsNews
Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis i...
Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer
SALT LAKE CITY, April 22, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancer...
Stella Diagnostics Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
SALT LAKE CITY, April 06, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancer...
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting
DENVER, March 02, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esop...
Stella Diagnostics Named ‘Best Clinical Proteomics Solution' of 2021 by Biotech Breakthrough Awards
BioTech Breakthrough Awards recognizes the world's best Life Sciences and Biotechnology companies, products and services BioTech Breakthrough Awards recognizes the world's best Life Sciences and Biote...
Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com
AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the C...